Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Avadomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 20/20 | 0.98 |
| ▸ | DDB1 known ✓ | Q16531 | 19/20 | 0.98 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.98 |
| ▸ | TNF | P01375 | 3/20 | 0.98 |
| ▸ | IL1B | P01584 | 3/20 | 0.98 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avadomide SCHEMBL29520051 | 1.00 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15515920 | 1.00 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL12099722 | 1.00 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29359950 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL634577 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15120730 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL282749 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29442249 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL20495583 | 0.94 | CRBN (0.90) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL20495228 | 0.94 | CRBN (0.90) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137793-A1 | Combination Therapies for Treating Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20250140352-A1 | SIMPLIFIED COMPOUND IDENTIFICATION | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2025-05-01 | — | — | US | disclosed |
| WO-2025042742-A1 | COMPOSITIONS COMPRISING ANTIBODIES THAT BIND BCMA AND CD3 AND METHODS OF TREATMENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024102948-A1 | FC RECEPTOR-HOMOLOG 5 (FCRH5) SPECIFIC BINDING MOLECULES AND BISPECIFIC T-CELL ENGAGING ANTIBODIES INCLUDING SAME AND RELATED METHODS | CELGENE CORPORATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240052064-A1 | ANTI-BCMA THERAPY IN AUTOIMMUNE DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-15 | — | — | US | disclosed |
| EP-4295918-A2 | BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA | Bristol-Myers Squibb Company (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-110167964-B | Combination of bispecific antibodies and immunopharmaceuticals against BCMA and CD3 for the treatment of multiple myeloma | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230364230-A1 | COMBINATION THERAPY FOR CANCER | ENGMAB SARL (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116601171-A | Combination therapy for cancer | 百时美施贵宝公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4211168-A1 | COMBINATION THERAPY FOR CANCER | Bristol-Myers Squibb Company (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-115803027-A | Methods of treating cytokine-related adverse events | 百时美施贵宝公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-4142722-A1 | METHODS OF TREATING CYTOKINE-RELATED ADVERSE EVENTS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230057602-A1 | METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3 | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| CN-115551539-A | anti-BCMA therapy in autoimmune disorders | 百时美施贵宝公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-4103224-A1 | ANTI-BCMA THERAPY IN AUTOIMMUNE DISORDERS | Bristol-Myers Squibb Company (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115279459-A | Methods of treatment using antibodies to BCMA and CD3 | 百时美施贵宝公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4054725-A1 | METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3 | Bristol-Myers Squibb Company (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-115003384-A | Treatment of cancer with HLA-A2/WT1 x CD3 bispecific antibodies and lenalidomide | 豪夫迈·罗氏有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220275093-A1 | TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND LENALIDOMIDE | HOFFMANN-LA ROCHE INC. (US) | 2022-09-01 | — | — | US | disclosed |
| WO-2022053652-A1 | COMBINATION THERAPY FOR CANCER | ENGMAB SÀRL (CH) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275093-A1 | TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND LENALIDOMIDE | HLA-B, HLA-C, HLA-DRB1 | CRBN 141/4885DDB1 1404/4885IKZF3 20/4885 |
| US-20260137793-A1 | Combination Therapies for Treating Cancer | CRBN, CMBL, CLEC4M | CRBN 1/4885DDB1 1069/4885IKZF3 432/4885 |
| US-20230364230-A1 | COMBINATION THERAPY FOR CANCER | KLRK1, CD22, CD2BP2 | CRBN 157/4885DDB1 104/4885IKZF3 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.